Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00215553 · ClinicalTrials.gov registry record · Phase 2
KL₄Surfactant Treatment in Patients With ARDS
A Phase 2 study, sponsored by Windtree Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 124
- Enrollment target
NCT00215553: Clinical Trial Phase 2 study, sponsored by Windtree Therapeutics.
NCT00215553 is a Phase 2 study that was terminated before completion, run by Windtree Therapeutics. The registered enrollment target is 124 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00215553, a Phase 2 study, was terminated before completion, sponsored by Windtree Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 124 participants
- Enrollment target
Study Summary
Lung wash with KL₄Surfactant of individual lung segments using a bronchoscope compared to usual care alone consisting primarily of assisted (mechanical) ventilation in patients with acute respiratory distress syndrome(ARDS).
Interventions
- DRUG A.1 Lucinactant
- OTHER B.3 SoC
- DRUG A.2 Lucinactant
- DRUG A.3 Lucinactant
- DRUG A.4 Lucinactant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2001-05 |
| Est. Completion | 2006-02 |
| Phase | Phase 2 |
Why NCT00215553 stopped before completion
NCT00215553 is an interventional study that assigns participants to a tested intervention. The registered 124 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 0 conditions, and to 5 interventions - of which A.1 Lucinactant is the first listed.
NCT00215553 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00215553 about?
NCT00215553 is a clinical study titled "KL₄Surfactant Treatment in Patients With ARDS". Lung wash with KL₄Surfactant of individual lung segments using a bronchoscope compared to usual care alone consisting primarily of assisted (mechanical) ventilation in patients with acute respiratory distress syndrome(ARDS).
What is the current status of trial NCT00215553?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 124 participants. The study started on 2001-05. Estimated completion is 2006-02.
What interventions are being tested in trial NCT00215553?
The interventions under investigation include: A.1 Lucinactant (DRUG), B.3 SoC (OTHER), A.2 Lucinactant (DRUG), A.3 Lucinactant (DRUG), A.4 Lucinactant (DRUG).
Who is sponsoring clinical trial NCT00215553?
This trial is sponsored by Windtree Therapeutics, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00215553's enrollment target sits among peer trials
124 564th of 2000 higher than 1,437 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523014 · 124 participants · Phase 2
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
- NCT02670707 · 124 participants · Phase 3
Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)
- NCT02830724 · 124 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
- NCT04748809 · 124 participants · NA
Effect of Anti-inflammatory Diet in Rheumatoid Arthritis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia